Background: To determine association between urine pH and OAB symptoms and to determine if urinary alkalization improves overactive bladder (OAB) symptoms. Methods: 659 patients with OAB were enrolled in this study between June 2012 and May 2014. 329 patients (group 1) were included in the final analysis. 201 adults were used as a control group (group 2). 24-hour urinary pH and the validated Turkish version of the OAB-V8 questionnaire were performed in patients. A 24-hour urine pH <6.2 was considered acidic urine. In the second part, a diet program was performed for 4 weeks in 30 participants. Urine pH values and OAB-V8 scoring results were recorded before the diet program and 2 and 4 weeks after the diet program. Results: Acidic urinary pH was determined in 61.4% of patients with OAB. There was a significant association between the presence of acidic urine and OAB. Also, the OAB-V8 scores of patients were significantly higher in patients with acidic urine than nonacidic urine. OAB-V8 scores of patients showed statistically significant improvement after diet therapy (17.87 ± 6.52 vs. 10.43 ± 7.17; p < 0.001). Conclusions: We found that acidic urinary pH was closely associated with OAB, and alkalization of urine improved lower urinary tract symptoms. We suggest that urinary pH should be considered as a parameter in treatment planning of patients with OAB.

Keywords:
Overactive bladder, Urinary alkalization, Urine pH
1.
Abrams P, Cardozo L, Fall M, et al: The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003;61:37-49.
2.
Haylen BT, de Ridder D, Freeman RM, et al; International Urogynecological Association; International Continence Society: An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfuntion. Neurourol Urodyn 2010;29:4-20.
3.
Stewart WF, Van Rooyen JB, Cundiff GW, et al: Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336.
4.
Irwin DE, Milsom I, Hunskaar S, et al: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1314; discussion 1314-1315.
5.
Michel MC, Chapple CR: Basic mechanisms of urgency: preclinical and clinical evidence. Eur Urol 2009;56:298-307.
6.
Brumfitt W, Hamilton-Miller JMT, Cooper J, Raeburn A: Relationship of urinary pH to symptoms of ‘cystitis'. Postgrad Med J 1990;66:727-729.
7.
Hohlbrugger G, Lentsch P: Intravesical ions, osmolality and pH influence the volume pressure response in the normal rat bladder, and this is more pronounced after DMSO exposure. Eur Urol 1985;11:127-130.
8.
Munday PE: Cymalon in the management of urinary tract symptoms. Genitourin Med 1990;66:460-462.
9.
Tarcan T, Mangir N, Ozgur MO, Akbal C: OAB-V8 Overactive Bladder Questionnaire Validation Study. Üroloji Bülteni 2012;21:113-116.
10.
Fjellstedt E, Denneberg T, Jeppsson JO, Tiselius HG: A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. Urol Res 2001;29:295-302.
11.
Janig W, Morrison J: Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception. Prog Brain Res 1986;67:87-114.
12.
Habler HJ, Janig W, Koltzenburg M: Activation of unmyelinated afferent fibers by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol 1990;425:545-562.
13.
Yoshimura N: Underlying mechanisms of interstitial cystitis/painful bladder syndrome (IC/PBS). Nishinihon J Urol 2009;71:243-252.
14.
Wong GY, Gavva NR: Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev 2009;60:267-277.
15.
Kobayashi H, Yoshiyama M, Zakoji H, Araki I: Sex differences in the expression profile of acid-sensing ion channels in the mouse urinary bladder: a possible involvement in irritative bladder symptoms. BJU Int 2009;104:1746-1751.
16.
Maalouf NM, Cameron MA, Moe OW, Skhaee K: Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol 2010;5:1277-1281.
17.
Hara S, Tsuji H, Ohmoto Y, et al: High serum uric acid level and low urine pH as predictors of metabolic syndrome: a retrospective cohort study in a Japanese urban population. Metabolism 2012;61:281-288.
18.
Tai HC, Chung SD, Ho CH, et al: Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes. J Clin Endocrinol Metab 2010;95:1143-1150.
19.
Gorbachinsky I, Akpinar H, Assimos DG: Metabolic syndrome and urological disease. Rev Urol 2010;12:e157-e180.
20.
Lee SR, Kim HJ, Kim A, Kim JH: Overactive bladder is not only overactive but also hypersensitive. Urology 2010;75:1053-1059.
21.
van Brummen HJ, Heintz AP, van der Vaart CH: The association between overactive bladder symptoms and objective parameters from bladder diary and filling cystometry. Neurourol Urodyn 2004;23:38-42.
22.
Ueda T, Yoshida T, Tanoue H, Ito M, Tamaki M, Ito Y, Yoshimura N: Urine alkalization improves the problems of pain and sleep in hypersensitive bladder syndrome. Int J Urol 2014;21:512-517.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.